1-Propyl-3-methyl-2-pyridone | 77475-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-Propyl-3-methyl-2-pyridone
• 英文别名: 3-Methyl-1-propylpyridin-2-one
• CAS: 77475-05-9
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: QOGBSSNYOHULBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-苯基马来酰亚胺 、 1-Propyl-3-methyl-2-pyridone 在 对苯二酚 作用下， 以 甲苯 为溶剂， 反应 32.0h， 以26%的产率得到N-Phenyl-endo-6-methyl-8-propyl-8-azabicyclo<2.2.2>oct-4-en-7-one-1,2-dicarboximide
  参考文献：
  名称：

  Shusherina, N. P.; Pilipenko, V. S.; Kireeva, O. K., Journal of Organic Chemistry USSR (English Translation), 1980, vol. 16, p. 2047 - 2051

  摘要：

  DOI：
• 作为产物：
  描述：

  3-Methyl-1-propylpyridin-1-ium;hydroxide 以52%的产率得到
  参考文献：
  名称：

  SHUSHERINA N. P.; PILIPENKO V. S.; KIREEVA O. K.; GELLER B. I.; STEPANYAN+, ZH. ORGAN. XIMII, 1980, 16, HO 11, 2390-2395

  摘要：

  DOI：

文献信息

• VICINAL PRIMARY DIAMINES ASSOCIATED WITH METAL AND/OR FREE RADICAL CHELATION MOTIFS, AND ACTIVE AGAINST CARBONYL AND OXIDATIVE STRESS, AND USE THEREOF
  申请人：UNIVERSITE AMIENS PICARDIE JULES VERNE

  公开号：US20180201602A1

  公开（公告）日：2018-07-19

  The invention relates to compounds of Formula I: or the salts thereof, as well as the use thereof in the pharmaceutical, cosmetic or agrofood industry.

  该发明涉及公式I的化合物：或其盐，以及在制药、化妆品或农业食品工业中的使用。
• Nitrogenous Fused Bicyclic Compound
  申请人：Takamuro Iwao

  公开号：US20080081817A1

  公开（公告）日：2008-04-03

  A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R 0 represents hydrogen, halogeno, etc.; R 1 represents a group represented by the formula (a) or (b); A represents a group represented by the formula (X) or (Y); D 1 , D 2 and D 3 each represents N or CH; R 2 represents halogeno or optionally halogenated lower alkyl, etc.; R 3 represents hydrogen or lower alkyl; and Q represents lower alkylene.)

  下面是一种新型的含氮融合双环化合物，其通式如下[1]，或其药理学上可接受的盐。它们具有出色的SK通道阻滞活性，是一种有用的药物。[I]（在公式中，R0代表氢，卤素等; R1代表由公式（a）或（b）表示的基团; A代表由公式（X）或（Y）表示的基团; D1，D2和D3分别表示N或CH; R2代表卤素或可选卤代的低碳基等; R3代表氢或低碳基; Q代表低碳链基）。
• Substituted pyridone compounds and methods of use
  申请人：Hu Essa

  公开号：US20080249090A1

  公开（公告）日：2008-10-09

  The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A 0-3 and R 1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新的化合物，能够调节c-kit受体，因此可用于治疗c-kit介导的疾病，包括各种炎症性、纤维化和/或肥大细胞介导的疾病，如肥大细胞增多症。该化合物具有一般的I式，其中A0-3和R1-6在此定义。本发明还涉及制药组合物、治疗c-kit介导的疾病的方法，以及制备本发明化合物的中间体和方法。
• Substituted Pyridone Compounds and Methods of Use
  申请人：HU Essa

  公开号：US20100160312A1

  公开（公告）日：2010-06-24

  The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various inflammatory, fibrotic and/or mast cell mediated diseases such as mastocytosis. The compounds have a general Formula I wherein A 0-3 and R 1-6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新的化合物，能够调节c-kit受体，因此可用于治疗c-kit介导的疾病，包括各种炎症、纤维化和/或肥大细胞介导的疾病，如肥大细胞增多症。该化合物具有一般式I，其中A0-3和R1-6在此定义。本发明还涉及制药组合物、治疗c-kit介导疾病的方法，以及制备本发明化合物的中间体和方法。
• Alicyclic Heterocyclic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182140A1

  公开（公告）日：2009-07-16

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P 1 and P 2 are CH or N, q and r are 0 to 2, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is —CO—, —SO 2 —, etc., and R 3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR 4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下式子所示的脂环杂环化合物或其药学上可接受的盐： 其中环A为杂环，环B为碳环，杂环等，P1和P2为CH或N，q和r为0至2，X为—NH—，—O—，—CH2—等，Y为— —，—CO—，—SO2—等，Z为—CO—，—SO2—等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基，用作CCR4功能调节剂，用于预防或治疗支气管哮喘，特应性皮炎等。